Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.75 |
| ▸ | CNR1 | P21554 | 5/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406886 | 1.00 | CNR2 (0.75) | CNR2CNR1P2RX7THRBEPHX2 | |
| SCHEMBL3408129 | 0.86 | CNR2 (1.00) | CNR2CNR1P2RX7THRB | |
| SCHEMBL3408133 | 0.86 | CNR2 (1.00) | CNR2CNR1P2RX7THRB | |
| SCHEMBL3413436 | 0.82 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3413432 | 0.82 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3457048 | 0.71 | P2RX7 (0.72) | CNR2CNR1P2RX7EPHX2POLB | |
| SCHEMBL858671 | 0.71 | COMT (0.55) | POLB | |
| SCHEMBL9895909 | 0.69 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9895230 | 0.68 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL10993582 | 0.66 | CNR2 (0.47) | CNR2CNR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2012-06-14 | — | — | US | disclosed |
| EP-2261211-A1 | 1,4-dihydropyridine derivatives and their uses | Université de Lille 2 Droit et Santé (FR) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885P2RX7 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.